Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.56 |
| ▸ | NOS1 | P29475 | 1/20 | 0.56 |
| ▸ | NOS2 | P35228 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.48 |
| ▸ | GSR | P00390 | 2/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4853049 | 1.00 | NOS3 (0.56) | NOS3NOS1NOS2SLC1A2SLC1A1 | |
| SCHEMBL25660616 | 0.96 | NOS3 (0.57) | NOS3NOS1NOS2SLC1A2SLC1A1 | |
| SCHEMBL25660443 | 0.88 | GSR (0.50) | NOS3NOS1NOS2GSRCYP1A2 | |
| SCHEMBL25661126 | 0.88 | GSR (0.50) | NOS3NOS1NOS2GSRCYP1A2 | |
| SCHEMBL20751441 | 0.85 | NOS1 (0.59) | NOS3NOS1NOS2SLC1A2SLC1A1 | |
| SCHEMBL21952409 | 0.85 | NOS1 (0.59) | NOS3NOS1NOS2SLC1A2SLC1A1 | |
| SCHEMBL4853803 | 0.82 | NOS1 (0.56) | NOS3NOS1NOS2SLC1A2SLC1A1 | |
| SCHEMBL4853808 | 0.82 | NOS1 (0.56) | NOS3NOS1NOS2SLC1A2SLC1A1 | |
| SCHEMBL25638860 | 0.81 | NOS1 (0.41) | NOS3NOS1NOS2SLC1A2SLC1A1 | |
| Homoserine SCHEMBL20299185 | 0.81 | SLC1A3 (0.45) | NOS3NOS1NOS2SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-14 | — | — | US | claimed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| EP-3898843-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | Takeda Pharmaceutical Company Limited (JP) | 2021-10-27 | — | — | EP | claimed |
| CN-113195641-A | Sulfoxonium ylide derivatives as probes for cysteine proteases | 武田药品工业株式会社 | 2021-07-30 | — | — | CN | claimed |
| WO-2020130152-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-25 | — | — | WO | claimed |
| WO-2004021981-A2 | METHODS FOR THE PREPARATION OF β-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2004-03-18 | — | — | WO | claimed |
| US-20030113882-A1 | Methods for the preparation of beta-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-06-19 | — | — | US | claimed |
| EP-0175180-A1 | Histargin-related compounds, a process for their preparation and their use as medicaments | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1986-03-26 | — | — | EP | claimed |
| JP-52148685-A | — | — | None | — | — | JP | disclosed |
| JP-52148685-A | — | — | None | — | — | JP | disclosed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| EP-4725952-A1 | COMPOUNDS COMPRISING NON-CANONICAL AMINO ACIDS AND USES THEREOF | ETH Zurich (CH) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260055430-A1 | LENTIVIRUS WITH ALTERED INTEGRASE ACTIVITY | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-0050503-A1 | Pharmacologically active pentapeptide derivatives | ELI LILLY AND COMPANY (US) | 1982-04-28 | — | — | EP | disclosed |
| US-4322339-A | Pharmacologically active peptides | ELI LILLY AND COMPANY (US) | 1982-03-30 | — | — | US | disclosed |
| US-4283329-A | ANALGESICS | ELI LILLY AND COMPANY (US) | 1981-08-11 | — | — | US | disclosed |
| EP-0030848-A2 | Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them | ELI LILLY AND COMPANY (US) | 1981-06-24 | — | — | EP | disclosed |
| JP-S52148685-A | PREPARATION OF O-ETHYL HOMOSERINE BY FERMENTATION | AJINOMOTO CO INC | 1977-12-10 | — | — | JP | disclosed |
| JP-S52148685-A | PREPARATION OF O-ETHYL HOMOSERINE BY FERMENTATION | AJINOMOTO CO INC | 1977-12-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055430-A1 | LENTIVIRUS WITH ALTERED INTEGRASE ACTIVITY | MUS81, L3MBTL1, SSU72 | NOS3 4756/4885NOS1 4819/4885NOS2 4838/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | NOS3 1214/4885NOS1 1488/4885NOS2 880/4885 |
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | CTSZ, CTSF, CTSL | NOS3 3522/4885NOS1 3436/4885NOS2 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.